Ocular Therapeutix (OCUL) Price Target Raised to $50 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ocular Therapeutix (OCUL) Target Raised to $49 at Oppenheimer; Positive Data Validates Platform
March 11, 2015 7:38 AM EDTOppenheimer analyst Yigal Nochomovitz reiterated an Outperform-rated and boosted his price target on Ocular Therapeutix (NASDAQ: OCUL) to $49.00 (from $42.00) saying positive Phase 3a data validates its technology platform.
commenetd, "Ocular reported positive OTX-DP Phase 3a top-line data in post-surgical pain/inflammation as expected. Both... More
Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c
March 10, 2015 6:46 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $505 thousand versus the consensus estimate of $200 thousand.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... MoreOcular Therapeutix (OCUL) Announces OTX-DP Met Primary Endpoints in First Phase 3
March 10, 2015 6:33 AM EDTOcular Therapeutix (NASDAQ: OCUL) announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (Sustained Release Dexamethasone), for the treatment of ocular inflammation and pain following cataract surgery. The Phase 3a study, which enrolled 247 patients, met both primary efficacy measures, achieving a statistically significant improvement in the reduction of inflammatory cells and pain. 33.7% of OTX-DP-treated patients showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14 following drug product insertion, compared to 14.6% of those receiving placebo... More
